Physician profile
John H Pula
NPI 1659573053
$2,900.46
in general payments reported to CMS, 2019-2025
14 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.45 · 2021: $378 · 2022: $2,129 · 2023: $111 · 2024: $118 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $368.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $2,332.38 | 2021-2022 | |
| Eyepoint US, INC. | $125.00 | 2021 | |
| Bausch & Lomb Americas INC. | $95.88 | 2023 | |
| Amgen INC. | $65.52 | 2024-2025 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $48.30 | 2023-2024 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $32.48 | 2025 | Syfovre |
| Alimera Sciences, INC. | $31.53 | 2024 | Yutiq, Iluvien |
| Glaukos Corporation | $29.78 | 2024 | Idose |
| Aerie Pharmaceuticals, INC. | $28.95 | 2021 | |
| Biogen, INC. | $26.14 | 2025 | Skyclarys |
| Shire North American Group INC | $25.45 | 2019 | |
| Sight Sciences, INC. | $20.30 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19.76 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $18.99 | 2025 | Tecnis Iol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.